CriteriaCaixa has renamed its venture arm Criteria Capital Risc and is targeting €300 million in early-stage investment by 2030.
The capital runs through two evergreen funds that back biotech, AI, photonics, cybersecurity, and software infrastructure.
Nearly 70% of the current portfolio is held in Spanish companies, with Portugal, Europe, and North America treated selectively.
Most venture funds work against the clock. Raise, deploy, exit, repeat, usually within a decade. CriteriaCaixa‘s investment arm doesn’t have one.
Now renamed Criteria Capital Risc, the manager is targeting €300 million in early-stage biotech and deeptech investment by 2030, capital with no fixed exit deadline attached.
